Colomer Bosch, Ramon ramon.colomer@uam.es
Actividades
- Artículos 257
- Libros 4
- Capítulos de libro 3
- Congresos 91
- Documentos de trabajo 1
- Informes técnicos 4
- Proyectos de investigación 1
- Tesis dirigidas 9
- Patentes o licencias de software 0
Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer
- Jimeno, R.
- Mouron, S.
- Salgado, R.
- Loi, S.
- Pérez-Mies, B.
- Sánchez-Bayona, R.
- Manso, L.
- Martínez, M.
- Garrido-García, A.
- Serrano-Pardo, R.
- Colomer, R.
- Quintela-Fandino, M.
Clinical & Translational Oncology (p. 1124-1131) - 1/4/2023
Editor: Springer Science and Business Media Deutschland GmbH
10.1007/s12094-022-03006-3 Ver en origen
- ISSN 1699048X
- ISSN/ISBN 1699-3055
- Dialnet
- iMarina
Progress and oncological outcome of neoadjuvant therapy in breast cancer patients during a 10-year period
- Ballesteros, A.I.
- López, M.P.
- Mondejar, R.
- Pacheco-Barcia, V.
- Donnay, O.
- Hernández, B.
- Romero-Laorden, N.
- Doblado, B.
- Álvarez López, R.M.
- Pérez-Fernández, E.
- Colomer, R.
Revista De Senologia Y Patologia Mamaria (p. 167-174) - 1/7/2022
Editor: Elsevier Doyma
10.1016/j.senol.2021.09.002 Ver en origen
- ISSN 02141582
- ISSN/ISBN 1578-1399
Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC
- Rogado, J.
- Pozo, F.
- Troule, K.
- Sánchez-Torres, J.M.
- Romero-Laorden, N.
- Mondejar, R.
- Donnay, O.
- Ballesteros, A.
- Pacheco-Barcia, V.
- Aspa, J.
- Al-Shahrour, F.
- Alfranca, A.
- Colomer, R.
Cancers - 1/6/2022
Editor: MDPI
10.3390/cancers14122898 Ver en origen
- ISSN 20726694
- ISSN/ISBN 2072-6694
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
- Dang, Chau
- Ewer, Michael S.
- Delaloge, Suzette
- Ferrero, Jean-Marc
- Colomer, Ramon
- de la Cruz-Merino, Luis
- Werner, Theresa L.
- Dadswell, Katherine
- Verrill, Mark
- Eiger, Daniel
- Sarkar, Sriparna
- de Haas, Sanne Lysbet
- Restuccia, Eleonora
- Swain, Sandra M.;
Cancers - 1/6/2022
10.3390/cancers14112596 Ver en origen
- ISSN 20726694
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
- Pacheco‐barcia, V.
- Muñoz, A.
- Castro, E.
- Ballesteros, A.I.
- Marquina, G.
- González‐díaz, I.
- Colomer, R.
- Romero‐laorden, N.
Cancers - 1/6/2022
Editor: MDPI
10.3390/cancers14122950 Ver en origen
- ISSN 20726694
- ISSN/ISBN 2072-6694
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
- García Alfonso, Pilar
- Saiz Rodríguez, M
- Mondéjar Solís, Rebeca
- Salazar Blanco, Juliana
- Páez López-Bravo, David
- Borobia Pérez, Alberto
- Safont, María José
- García García, I
- Colomer Bosch, Ramón
- García González, X
- Herrero, M J
- López Fernández, Luis Andrés
- Abad Santos, Francisco
Clinical & Translational Oncology (p. 483-494) - 1/3/2022
10.1007/s12094-021-02708-4 Ver en origen
- ISSN 1699048X
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
- Mouron S
- Bueno MJ
- Lluch A
- Manso L
- Calvo I
- Cortes J
- Garcia-Saenz JA
- Gil-Gil M
- Martinez-Janez N
- Apala JV
- Caleiras E
- Ximénez-Embún P
- Muñoz J
- Gonzalez-Cortijo L
- Murillo R
- Sánchez-Bayona R
- Cejalvo JM
- Gómez-López G
- Fustero-Torre C
- Sabroso-Lasa S
- Malats N
- Martinez M
- Moreno A
- Megias D
- Malumbres M
- Colomer R
- Quintela-Fandino M
Nature Communications - 1/12/2022
10.1038/s41467-022-35065-z Ver en origen
- ISSN 20411723
Excess weight and anti-PD-1 immune checkpoint inhibitor’s outcomes in non-small cell lung cancer
- Rogado, J.
- Pozo, F.
- Troulé, K.
- Sánchez-Torres, J.M.
- Romero-Laorden, N.
- Mondejar, R.
- Donnay, O.
- Ballesteros, A.
- Pacheco-Barcia, V.
- Aspa, J.
- Al-Shahrour, F.
- Alfranca, A.
- Colomer, R.
Clinical & Translational Oncology (p. 2241-2249) - 1/11/2022
Editor: Springer Science and Business Media Deutschland GmbH
10.1007/s12094-022-02887-8 Ver en origen
- ISSN 1699048X
- ISSN/ISBN 1699-3055
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
- Garrido, P.
- Hladun, R.
- de Álava, E.
- Álvarez, R.
- Bautista, F.
- López-Ríos, F.
- Colomer, R.
- Rojo, F.
Clinical & Translational Oncology (p. 1529-1541) - 1/8/2021
Editor: Springer Science and Business Media Deutschland GmbH
10.1007/s12094-021-02558-0 Ver en origen
- ISSN 1699048X
- ISSN/ISBN 1699-3055
- Dialnet
- iMarina
The Pharmacological or Genetic Blockade of Endogenous De Novo Fatty Acid Synthesis Does Not Increase the Uptake of Exogenous Lipids in Ovarian Cancer Cells
- Grunt, Thomas W.
- Lemberger, Lisa
- Colomer, Ramon
- Lopez-Rodriguez, Maria Luz
- Wagner, Renate;
Frontiers In Oncology - 13/4/2021
10.3389/fonc.2021.610885 Ver en origen
- ISSN 2234943X
Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated …
- Chau Dang
- Michael S Ewer
- Suzette Delaloge
- Jean-Marc Ferrero
- Mark Verrill
- Ramon Colomer
- Claudia Vieira
- Luis de la Cruz Merino
- Jennifer Lucas
- Theresa L Werner
- Hannah Douthwaite
- Denise Bradley
- Maeve Waldron-Lynch
- Jennifer Eng-Wong
- Sandra M Swain
1/1/2018
- iMarina
Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
- J Rogado
- MD Fenor De La Maza
- V Pacheco-Barcia
- JM Serra
- P Toquero
- B Vera
- A Ballesteros
- R Mondejar
- O Donnay
- B Obispo
- R Colomer
- JM Sanchez-Torres
1/1/2017
- iMarina
Medicina de precisión en oncología: Éxitos y perspectivas bioéticas
- Ramón Colomer Bosch
Bioética Y Cáncer (p. 17-26) - 1/1/2020
- iMarina
Fatty acid metabolism in cancer cell survival: A new anti-cancer target
- Porta, Rut
- Colomer, Ramon
- Puig, Teresa;
Cell Respiration And Cell Survival: Processes, Types And Effects (p. 193-208) - 1/12/2011
- iMarina
Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+breast cancer in Spain
- Abanell, J.
- Ciruelos, E.
- De la Haba, J.
- Martin, M.
- Munoz-Molina, B.
- De Salas-Cansado, M.
- Colomer, R.;
Cancer Research - 1/1/2017
10.1158/1538-7445.sabcs16-p3-12-02 Ver en origen
- ISSN 00085472
Estimating costs of relapsing HER2+breast cancer in Spain
- Colomer, R.
- Ciruelos, E.
- De la Haba, J.
- Martin, M.
- De Salas-Cansado, M.
- Munoz-Molina, B.
- Albanell, J.;
Cancer Research - 1/1/2017
10.1158/1538-7445.sabcs16-p3-12-05 Ver en origen
- ISSN 00085472
Could a systemic inflammation response index (SIRI) predict overall survival (OS) in metastatic pancreatic cancer (PC)?
- Pacheco-Barcia, V.
- Donnay, O.
- Mondejar, R.
- Rogado, J.
- Fenor de la Maza, M. D.
- Colomer, R.;
Annals Of Oncology - 1/1/2017
- ISSN 09237534
- iMarina
Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
- Rogado, J.
- Pacheco-Barcia, V.
- Fenor De la Maza, M. D.
- Serra, J. M.
- Toquero, P.
- Vera, B.
- Obispo, B.
- Mondejar, R.
- Ballesteros, A.
- Donnay, O.
- Colomer, R.
- Sanchez-Torres, J. M.;
Journal Of Thoracic Oncology (p. S1915-S1916) - 1/1/2017
- ISSN 15560864
- iMarina
Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
- J Rogado
- Fenor De La Maza
- V Pacheco-Barcia
- J Serra
- P Toquero
- B Vera
- A Ballesteros
- R Mondéjar
- O Donnay
- B Obispo
- R Colomer
- J Sánchez-Torres
Journal Of Thoracic Oncology (p. S2107-S2108) - 1/1/2017
- ISSN 15560864
- iMarina
Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer
- Swain, S. M.
- Ewer, M. S.
- Viale, G.
- Delaloge, S.
- Ferrero, J. M.
- Verrill, M.
- Colomer, R.
- Vieira, C.
- Werner, T. L.
- Douthwaite, H.
- Bradley, D.
- Waldron-Lynch, M.
- Eng-Wong, J.
- Dang, C.;
Cancer Research - 1/1/2017
10.1158/1538-7445.sabcs16-p4-21-41 Ver en origen
- ISSN 00085472
Exploiting cross-talk between lipid metabolism and oncogenic signaling for treatment of ovarian cancer
- Wagner, R.
- Stuebiger, G.
- Lanzerstorfer, P.
- Weghuber, J.
- Karteris, E.
- Nowikovsky, K.
- Wilfinger, N.
- Colomer, R.
- Lopez-Rodriguez, M. L.
- Grunt, T. W.;
European Journal Of Cancer (p. S61-S61) - 1/1/2016
10.1016/s0959-8049(16)61211-x Ver en origen
- ISSN 09598049
Phase I trial of the combination of the multikinase inhibitor nintedanib plus letrozole: A window of opportunity trial in adjuvant hormone-receptor positive breast cancer (HRPBC).
- Rodriguez, Laura Medina
- Guerra, Juan Antonio
- Malon, Diego
- Laura, Rodriguez
- Colomer, Ramon
- Quintela-Fandino, Miguel;
Journal Of Clinical Oncology - 1/1/2016
10.1200/jco.2016.34.15_suppl.tps615 Ver en origen
- ISSN 0732183X
RESPONSE TO TARGETED THERAPY AND HEALTHCARE RESOURCE UTILIZATION (HRU): A EUROPEAN RETROSPECTIVE CHART REVIEW STUDY IN PATIENTS WITH HER2+METASTATIC BREAST CANCER
- Colomer, R.
- Hall, P.
- Szkultecka-Debek, M.
- Bondi, R.
- Flinois, A.
- Le Cleach, J.;
Value In Health (p. A742-A742) - 1/1/2016
10.1016/j.jval.2016.09.2260 Ver en origen
- ISSN 10983015
TREATMENT RATES IN PATIENTS WITH HER2+METASTATIC BREAST CANCER AND THE FACTORS INFLUENCING TREATMENT DECISION
- Colomer, R.
- Hall, P.
- Szkultecka-Debek, M.
- Bondi, R.
- Flinois, A.
- Auziere, S.
- Le Cleach, J.;
Value In Health (p. A764-A765) - 1/1/2016
10.1016/j.jval.2016.09.2386 Ver en origen
- ISSN 10983015
[Generalized cutaneous-nodal metastatic spread as initial manifestation of the recurrence of a gastric adenocarcinoma]
- Sanchez-Munoz, A
- Gravalos Castro, C
- Colomer Bosch, R
- Garcia Velasco, A
- Garcia, J P
- Cortes-Funes, H
Revista Clinica Espanola (p. 597-598) - 1/1/2003
- ISSN 15781860
- iMarina
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, monarchE Committee Members and Investigators
Journal Of Clinical Oncology (p. 3987-3998) - 1/12/2020
- ISSN 0732183X
- iMarina
A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer
- Antón A, Hornedo J, Lluch A, Massuti B, Corral M, Colomer R
Clinical Breast Cancer (p. 286-91) - 1/1/2003
10.3816/cbc.2003.n.034 Ver en origen
- ISSN 15268209
Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization
- Arranz, R.
- García-Alfonso, P.
- Sobrino, P.
- Zamora, P.
- Carrión, R.
- García-Laraña, J.
- Pérez, G.
- López, J.
- Lavilla, E.
- Lozano, M.
- Rayón, C.
- Colomer, R.
- González Barón, M.
- Flores, E.
- Pérez-Manga, G.
- Fernández-Rañada, J.M.
Journal Of Clinical Oncology (p. 1538-1546) - 1/1/1998
Editor: American Society of Clinical Oncology
10.1200/jco.1998.16.4.1538 Ver en origen
- ISSN 0732183X
- ISSN/ISBN 0732-183X
- Dialnet
- iMarina
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.
- Hitt, R
- Paz-Ares, L
- Hidalgo, M
- Colomer, R
- Brandariz, A
- Pena, M
- Alvarez-Vicent, J
- Hornedo, J
- Cortes-Funes, H;
Seminars In Oncology (p. S19-20) - 1/12/1997
- ISSN 00937754
- iMarina
Índice de Respuesta Inflamatoria Sistémica (IRIS): Factor Pronóstico en el Cáncer de Páncreas
- Rebeca Mondéjar Solís (Director)
- Ramón Colomer Bosch (Director) Doctorando: Pacheco Barcia, Vilma Emilia
28/1/2021
- iMarina
Cambios en el perfil inmunohistoquímico tras tratamiento neoadyuvante en pacientes con cáncer de mama
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director)
- Miguel Martín Giménez (Director) Doctorando: Rebeca Mondéjar Solís
1/1/2016
- iMarina
El fenotipo basal-her2 en el cáncer de mama: caracterización clínico-molecular e implicaciones terapéuticas
- Colomer Bosch, Ramon (Autor o Coautor)
- Javier Abel Menéndez Menéndez (Director)
- Ramón Colomer Bosch (Director) Doctorando: Begoña Martín Castillo
1/1/2016
- iMarina
Efectos de la inhibición de la síntesis de ácidos grasos en la eficacia de los tratamientos antineoplásicos
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director) Doctorando: Alejandro Vázquez Martín
1/1/2007
- iMarina
Estudio fase i/ii con dosis altas de mitoxantrone y ciclofosfamida sin soporte hematopoyético para el tratamiento de tumores de alto riesgo y metastásicos
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director)
- Rafael Enríquez de Salamanca (Director) Doctorando: José Luis Pérez Gracia
1/1/2004
- iMarina
Características y evolución del cáncer de mama metástásico al diagnóstico: comparación con las recidivas del cáncer de mama inicialmente localizado
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director)
- Rafael Enríquez de Salamanca (Director) Doctorando: Antonio Jimeno Largo
1/1/2003
- iMarina
Importancia de la dosis de antraciclinas en el tratamiento adyuvante del cáncer de mama
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director)
- Rafael Enríquez de Salamanca Lorente (Director) Doctorando: María Luz Amador Muñoz
1/1/2002
- iMarina
Ácidos grasos en la progresión del cáncer de mama: implicaciones terapéuticas
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director) Doctorando: Javier Abel Menéndez Menéndez
1/1/2001
- iMarina
Utilidad de la expresión de p53 en tumores de mama como factor pronóstico y predictor de la respuesta al tratamiento
- Colomer Bosch, Ramon (Autor o Coautor)
- Ramón Colomer Bosch (Director) Doctorando: Cecilia Guzman Zapater
1/1/1996
- iMarina
Este/a investigador/a no tiene patentes o licencias de software.
Perfiles de investigador/a
-
ORCID
-
Publons
-
Scopus Author ID
-
Dialnet id